Satsuma Pharmaceuticals Inc

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

- Completed enrollment in the SUMMIT pivotal Phase 3 efficacy trial of STS101, randomizing more than 1,400 subjects -

Satsuma Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Progress in STS101 Development Program

- More than 1,400 subjects randomized - -  Satsuma expects to announce topline SUMMIT trial results in Q4 2022 -

Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

Oral Presentation: Initial Data from ASCEND Study Highlights STS101's Long-Term Safety and Tolerability Oral Presentation: Initial Data from ASCEND Study Highlights STS101's Long-Term Safety and Tolerability

Satsuma Pharmaceuticals Announces Five Abstracts Accepted for Presentation at The American Headache Society's 64th Annual Scientific Meeting

Thursday, June 16th @ 10:30 a.m. ET Thursday, June 16th @ 10:30 a.m. ET

Satsuma Pharmaceuticals Hosting Key Opinion Leader Webinar on the Acute Treatment of Migraine, DHE, and STS101

SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference and invites investors to participate via webcast or in-person in Miami, FL on May 24 -25, 2022. Please see additional details below:

Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing and on track to read out topline results in Q4 2022 -

Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing; key trial on track to read out topline results in Q4 2022 -

Satsuma Pharmaceuticals Reports 2021 Full Year and Fourth Quarter Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that four abstracts highlighting STS101 and its differentiating features were selected for presentation and will be shared at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2 to April 7, 2022. Full abstracts are now available on the AAN website.

Satsuma Pharmaceuticals Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference and invites investors to participate via webcast. Please see additional details below:

Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference

- STS101 SUMMIT Phase 3 efficacy trial enrollment ongoing, with topline results expected second half of 2022 -

Satsuma Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

DELRAY BEACH, Fla., Nov. 9, 2021 /PRNewswire/ -- Cyrano Therapeutics, a clinical stage regenerative medicine company developing a novel intranasal therapy to restore smell and flavor function, today announced that it has appointed biopharmaceutical industry veteran John Kollins to its board of directors.

Cyrano Therapeutics Announces the Appointment of John Kollins to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present in the month of November at the following conferences and invites investors to participate via webcast and in virtual one-on-one meetings. Please see additional details below:

Satsuma Pharmaceuticals to Present at Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced the appointment of Mutya Harsch, JD to its Board of Directors, effective immediately. Ms. Harsch is a highly regarded and established pharmaceutical industry professional who brings over 20 years of legal, corporate governance, corporate transaction, and operating experience to Satsuma. She currently serves as General Counsel, Chief Legal Officer and Secretary of VYNE Therapeutics, a publicly traded biopharmaceutical company.

Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference and participate in one-on-one meetings with investors. The Conference will be held virtually with all participants joining remotely from September 13th – 15th.

Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

- Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022-

Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced randomization of the first subject in its SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine.

Satsuma Pharmaceuticals Announces First Subject Randomized in SUMMIT™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, President and Chief Executive Officer, is scheduled to present at the SVB Leerink CNS Forum on Tuesday, June 29, 2021 at 3:40 PM Eastern Time. The conference will be held virtually with participants joining remotely on June 29th & 30th.

Satsuma Pharmaceuticals to Present at SVB Leerink's CNS Forum

The stock price of Satsuma Pharmaceuticals Inc (NASDAQ: STSA) increased by over 15% pre-market. This is why it happened.

STSA Stock Price Increases Over 15% Pre-Market: Why It Happened

- All three dose strengths of STS101, administered with improved 2 nd -generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile -

Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths

-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022-

Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights

Satsuma Pharmaceuticals (STSA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Satsuma Pharmaceuticals (STSA)

Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Satsuma's lead and only candidate STS101 targeting treatment of acute migraines failed a pivotal trial in September last year. After a long silence, management has announced that it will launch a 2nd pivotal trial sometime in 2022, and has taken learnings from the 1st trial is confident of success.

Satsuma: Launch Of 2nd Pivotal Trial For Migraine Med Ought To Cheer Share Price

Satsuma Pharmaceuticals Inc (NASDAQ: STSA) will conduct a new Phase 3 efficacy trial for STS101 (dihydroergotamine (DHE) nasal powder) as an acute treatment option for migraine. The study will start in mid-2021, with topline data expected in the second half of 2022.

News for Satsuma Pharmaceuticals Inc Stock (STSA)